Tiziano Barbui

Q: What Schools Are Affiliated With Tiziano Barbui

Tiziano Barbui is affiliated with the following schools: University of Milan, University of Oxford, Stanford University, University of Florence, University of Vienna

Tiziano Barbui's AcademicInfluence.com Rankings

Tiziano Barbui

Physics

#3285

World Rank

#4699

Historical Rank

physics Degrees

Download Badge

Physics

Tiziano Barbui's Degrees

PhD Physics University of Milan
Masters Physics University of Milan
Bachelors Physics University of Milan

Why Is Tiziano Barbui Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Tiziano Barbui's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. (2012) (1499)
Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor (1990) (1379)
Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. (2003) (968)
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. (2007) (893)
Efficacy and safety of low-dose aspirin in polycythemia vera. (2004) (856)
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. (1995) (790)
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. (2011) (745)
Lupus Anticoagulant IgG's (LA) Are Not Directed to Phospholipids only, but to a Complex of Lipid-Bound Human Prothrombin (1991) (637)
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. (2005) (633)
Cardiovascular events and intensity of treatment in polycythemia vera. (2013) (621)
Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. (2000) (616)
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. (2014) (552)
The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. (1997) (528)
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study (2013) (506)
Molecular Remission in PML/RARα-Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy (1997) (488)
A randomized clinical trial of high‐intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) 1 (2005) (457)
Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. (2010) (455)
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. (2007) (454)
Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. (1990) (448)
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. (1996) (444)
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. (2001) (444)
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). (2012) (424)
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. (2011) (415)
Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. (2003) (406)
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. (2005) (403)
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). (2009) (396)
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. (2013) (381)
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. (2007) (366)
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. (2011) (365)
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion (2018) (346)
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet (2018) (342)
A multicenter study of treatment of primary CNS lymphoma (2002) (330)
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. (2012) (328)
Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden (2007) (328)
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments (2008) (325)
Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. (2007) (325)
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis (2016) (308)
Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. (2007) (306)
Myeloproliferative neoplasms and thrombosis. (2013) (303)
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. (2011) (290)
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. (2017) (287)
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. (2013) (269)
Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. (2004) (267)
Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Tra (2000) (256)
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. (2007) (250)
International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. (2022) (249)
Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia (1992) (246)
Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation (2006) (243)
A pilot study of the Histone‐Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms (2010) (235)
Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. (1990) (234)
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. (2008) (231)
High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. (1991) (228)
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. (2009) (227)
A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. (2012) (227)
Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. (1997) (224)
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). (2003) (219)
Thrombosis in primary myelofibrosis: incidence and risk factors. (2009) (213)
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group (2015) (211)
Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. (2005) (210)
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long‐term follow‐up of a randomized clinical trial (2000) (209)
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. (2009) (207)
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis (2017) (205)
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. (2013) (200)
Anticoagulant Activity of β2-Glycoprotein I Is Potentiated by a Distinct Subgroup of Anticardiolipin Antibodies (1992) (200)
An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms (2014) (198)
Defibrotide for the treatment of hepatic veno‐occlusive disease: results of the European compassionate‐use study (2000) (195)
Leukocytosis and risk stratification assessment in essential thrombocythemia. (2007) (192)
The haematocrit and platelet target in polycythemia vera (2007) (186)
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk‐stratification, and management (2017) (182)
Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. (2005) (178)
Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. (1999) (177)
V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. (2007) (177)
Different Anticoagulant and Immunological Properties of Anti-Prothrombin Antibodies in Patients with Antiphospholipid Antibodies (1997) (175)
Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. (2007) (173)
Thrombotic and Hemorrhagic Complications in Patients with Mechanical Heart Valve Prosthesis Attending an Anticoagulation Clinic (1993) (173)
Different Prevalence of Thromboembolism in the Subtypes of Congenital Antithrombin III Deficiency:Review of 404 Cases (1987) (172)
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera (2000) (169)
Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. (2007) (167)
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. (2002) (167)
Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies. (1995) (165)
Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma. (1999) (165)
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia (2015) (165)
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk‐stratification and management (2018) (164)
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea (2013) (164)
Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. (2000) (164)
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3 (2011) (162)
Clinical Manifestations and Management of Inherited Thrombophilia: Retrospective Analysis and Follow-up after Diagnosis of 238 Patients with Congenital Deficiency of Antithrombin III, Protein C, Protein S (1994) (161)
Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. (1999) (160)
Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study (1990) (157)
Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. (2008) (151)
Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? (2009) (150)
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. (2011) (148)
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk‐stratification and management (2020) (145)
Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. (2007) (145)
Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. (1991) (143)
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process (2010) (143)
Lymphomas occurring late after solid-organ transplantation: Influence of treatment on the clinical outcome (2002) (143)
Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. (1995) (140)
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria (2012) (139)
Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. (2000) (137)
Preventing Fungal Infection in Neutropenic Patients with Acute Leukemia: Fluconazole Compared with Oral Amphotericin B (1994) (137)
A new procoagulant in acute leukemia. (1988) (137)
Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. (1991) (136)
Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis (2015) (135)
How I treat patients with polycythemia vera. (2007) (131)
Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. (2007) (130)
Constitutive expression of the interleukin-6 gene in chronic lymphocytic leukemia. (1989) (129)
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study (2005) (128)
Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. (1998) (128)
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations (2011) (127)
Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus-8 (1999) (124)
The Impact of All-trans-Retinoic Acid on the Coagulopathy of Acute Promyelocytic Leukemia (1998) (123)
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both (2016) (121)
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. (2017) (121)
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. (2000) (120)
Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. (1997) (119)
The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. (1998) (119)
Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. (1998) (119)
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy (2013) (118)
Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells (2003) (117)
Thrombosis during Pregnancy and Surgery in Patients with Congenital Deficiency of Antithrombin III, Protein C, Protein S (1994) (116)
Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. (2008) (115)
Outrageous prices of orphan drugs: a call for collaboration (2018) (114)
All‐trans‐RETINOIC ACID INCREASES ADHESION TO ENDOTHELIUM OF THE HUMAN PROMYELOCYTIC LEUKAEMIA CELL LINE NB4 (1996) (111)
Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. (2005) (111)
Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. (2008) (110)
Hydroxyurea‐related toxicity in 3,411 patients with Ph'‐negative MPN (2012) (109)
Chronic myeloproliferative disorders. (2003) (107)
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study (2013) (105)
A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group (2007) (104)
Evidence and expertise in the management of polycythemia vera and essential thrombocythemia (2008) (104)
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. (2014) (103)
Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015) (100)
Pegylated Interferon Alfa-2a for Polycythemia Vera or Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea. (2019) (99)
T cell receptor beta chain gene rearrangements in lymphoproliferative disorders of large granular lymphocytes/natural killer cells (1985) (99)
The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. (2016) (98)
Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet‐derived microvesicles (1993) (98)
JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. (2009) (97)
Increased Thromboxane Biosynthesis in Essential Thrombocythemia (1995) (97)
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk‐stratification and management (2015) (96)
Detection of ALL-1/AF4 fusion transcript by reverse transcription-polymerase chain reaction for diagnosis and monitoring of acute leukemias with the t(4;11) translocation. (1993) (95)
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. (2014) (94)
Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis (2017) (94)
Anti-Glycoprotein Ib/IX and llb/llla Antibodies in Patients with Antiphospholipid Antibodies (1994) (91)
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. (2012) (89)
Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils. (2005) (87)
Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery (1993) (87)
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F (2008) (87)
Essential thrombocythemia treatment algorithm 2018 (2018) (86)
Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. (2008) (85)
The Effect of Very-low-dose Warfarin on Markers of Hypercoagulation in Metastatic Breast Cancer: Results from a Randomized Trial (1998) (84)
Thrombocytosis and thrombosis. (2007) (84)
ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. (2002) (82)
Disseminated intravascular coagulation in acute leukemia. (2001) (81)
A Polycythemia Vera Updated: Diagnosis, Pathobiology, and Treatment. (2000) (79)
Antiphospholipid antibodies in early repeated abortions: a case-controlled study. (1988) (78)
Platelet-derived Microvesicles in Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome (1996) (78)
Bleeding and thrombosis in acute leukemia: what does the future of therapy look like? (2007) (78)
Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis. (1989) (78)
Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients (2012) (78)
Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. (2019) (77)
Hemostatic complications in young patients with essential thrombocythemia. (1990) (77)
Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. (2014) (76)
White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. (2015) (75)
Risk-adapted therapy in essential thrombocythemia and polycythemia vera. (2005) (75)
High‐dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma (2003) (74)
Factor VIII-related properties in platelets from patients with von Willebrand's disease. (1978) (74)
When and how to treat essential thrombocythemia. (2005) (74)
What are RBC-transfusion-dependence and -independence? (2011) (72)
Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. (2014) (72)
Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy (2013) (72)
Retinoic acid and granulocyte colony-stimulating factor synergistically induce leukocyte alkaline phosphatase in acute promyelocytic leukemia cells. (1994) (71)
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients (2016) (71)
Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients (2014) (70)
Guidelines for Clotting Studies in Cancer Patients (1993) (69)
Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. (1989) (69)
Polycythemia vera treatment algorithm 2018 (2018) (69)
Inherited protein C deficiency and nonhemorrhagic arterial stroke in young adults (1991) (69)
Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group (2016) (69)
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib (2021) (69)
Autoimmunity and b‐cell dysfunction in chronic proliferative disorders of large granular lymphocytes/natural killer cells (1989) (67)
Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. (2008) (67)
The Risk of Thrombosis in Patients with Lupus Anticoagulants Is Predicted by their Specific Coagulation Profile (1999) (67)
Diagnosis and Treatment of Polycythemia Vera and Possible Future Study Designs of the PVSG (2000) (66)
Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. (2008) (66)
Antiphospholipid antibodies in lymphoma: prevalence and clinical significance. (2004) (66)
Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. (1997) (66)
Thrombocytopenia in the antiphospholipid syndrome (1996) (66)
Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function. (1983) (65)
Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia (1984) (65)
Different Incidence of Venous Thrombosis in Patients with Inherited Deficiencies of Antithrombin III, Protein C and Protein S (1994) (65)
Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. (2012) (64)
Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU) (2010) (64)
Masked polycythemia vera diagnosed according to WHO and BCSH classification (2014) (64)
Clinical parameters for determining when and when not to treat essential thrombocythemia. (1999) (64)
Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): first report from the Italian Registry. Italian Registry of Antiphospholipid Antibodies (IR-APA). (1993) (64)
Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis. (1999) (64)
AM580, a stable benzoic derivative of retinoic acid, has powerful and selective cyto-differentiating effects on acute promyelocytic leukemia cells. (1996) (63)
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). (2008) (63)
Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. (2010) (63)
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists (2016) (63)
Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. (2003) (63)
Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. (2008) (62)
Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project (2014) (61)
Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). (2009) (60)
T cell receptor (alpha, beta, gamma) gene rearrangements and expression in normal and leukemic large granular lymphocytes/natural killer cells. (1987) (60)
Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-trans-retinoic acid. (1994) (59)
Cancer Procoagulant in Acute Non Lymphoid Leukemia: Relationship of Enzyme Detection to Disease Activity (1990) (59)
Front-Line Treatment of Acute Promyelocytic Leukemia with AIDA Induction Followed by Risk-Adapted Consolidation: Results of the AIDA-2000 Trial of the Italian GIMEMA Group. (2004) (59)
Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF) (2012) (58)
Masked polycythemia Vera (mPV): Results of an international study (2013) (58)
Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia. (1984) (58)
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia (2009) (57)
Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia (2013) (57)
CD 20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia : further regulation by CD 55 and CD 59 (2001) (56)
Masked polycythemia Vera (mPV): Results of an international study (2014) (56)
Personalized management of essential thrombocythemia—application of recent evidence to clinical practice (2013) (56)
The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? (2004) (56)
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study (2019) (54)
Danazol for the treatment of idiopathic thrombocytopenic purpura. (1985) (54)
The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibitions (1994) (54)
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. (1996) (54)
All-trans-retinoic acid counteracts endothelial cell procoagulant activity induced by a human promyelocytic leukemia-derived cell line (NB4). (1996) (53)
Rethinking the diagnostic criteria of polycythemia vera (2014) (52)
Trends in mortality from leukemia in subsequent age groups (2000) (52)
Myeloproliferative disease in pregnancy and other management issues. (2006) (52)
Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms (2010) (52)
Antiphospholipid syndrome: clinical and diagnostic utility of laboratory tests. (2005) (51)
A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea. (2009) (51)
Coagulopathy of Acute Promyelocytic Leukemia (2001) (51)
Leukocytosis as an important risk factor for arterial thrombosis in WHO‐defined early/prefibrotic myelofibrosis: An international study of 264 patients (2012) (51)
Antiphospholipid Antibodies: Predictive Value of Laboratory Tests (1997) (51)
A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group (2007) (51)
Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. (2016) (51)
Treatment of polycythemia vera. (1998) (50)
Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis (2013) (50)
Pregnancy complications predict thrombotic events in young women with essential thrombocythemia (2014) (50)
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients (2015) (49)
High dose cytosine arabinoside in the initial treatment of adults with acute lymphoblastic leukaemia. (1990) (49)
The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera (2011) (49)
The impact of perioperative transfusion of blood products on survival after pediatric liver transplantation (2012) (48)
Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. (2017) (48)
Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties. (2006) (48)
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia (2010) (48)
Cutaneous manifestations associated with antiphospholipid antibodies in patients with suspected primary antiphospholipid syndrome: a case-control study. (1993) (47)
Anti‐prothrombin IgG from patients with anti‐phospholipid antibodies inhibits the inactivation of factor Va by activated protein C (2005) (47)
HEREDITARY DYSFUNCTIONAL PROTEIN C (PROTEIN C BERGAMO) AND THROMBOSIS (1984) (47)
Expression of leukocyte alkaline phosphatase gene in normal and leukemic cells: regulation of the transcript by granulocyte colony-stimulating factor. (1990) (47)
Front-line therapy in polycythemia vera and essential thrombocythemia. (2012) (47)
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases (2018) (47)
Covid-19 and gender: lower rate but same mortality of severe disease in women—an observational study (2021) (46)
A reappraisal of the benefit‐risk profile of hydroxyurea in polycythemia vera: A propensity‐matched study (2017) (46)
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera (2014) (46)
Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant. (2001) (46)
Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG) (1999) (45)
Lupus Anticoagulants and Thrombosis: Clinical Association of Different Coagulation and Immunologic Tests (2000) (45)
The effect of arterial hypertension on thrombosis in low‐risk polycythemia vera (2017) (44)
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies (2014) (44)
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) (2014) (43)
Negative selection of peripheral blood stem cells  to support a tandem autologous transplantation  programme in multiple myeloma (2002) (43)
All-trans retinoic acid and cyclic adenosine monophosphate cooperate in the expression of leukocyte alkaline phosphatase in acute promyelocytic leukemia cells. (1995) (43)
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group (2016) (43)
Innovative two-step negative selection of granulocyte colony-stimulating factor-mobilized circulating progenitor cells: adequacy for autologous and allogeneic transplantation. (1998) (43)
Myeloproliferative neoplasms: Morphology and clinical practice (2016) (43)
Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia. (1996) (43)
Minimal residual disease in acute lymphoblastic leukemia detected by immune selection and gene rearrangement analysis. (1989) (43)
Antiphospholipid antibodies and thrombosis: strength of association. (2003) (43)
Three Abnormal Fibrinogen Variants with the Same Amino Acid Substitution (γ 275 Arg → His): Fibrinogens Bergamo II, Essen and Perugia (1986) (42)
Treatment of essential thrombocythemia with special emphasis on leukemogenic risk (1999) (42)
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation (2010) (42)
Fatal pulmonary embolism and antithrombin III deficiency in adult lymphoblastic leukaemia during L-asparaginase therapy. (1983) (41)
Cancer procoagulant in acute lymphoblastic leukemia (1990) (41)
Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice. (2015) (41)
Aspirin and risk of bleeding in patients with thrombocythemia. (1987) (41)
How to manage children and young adults with myeloproliferative neoplasms (2012) (41)
DOES SPLENECTOMY ENHANCE RISK OF AIDS IN HIV-POSITIVE PATIENTS WITH CHRONIC THROMBOCYTOPENIA? (1987) (41)
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms (2017) (40)
Platelet Activation in Myeloproliferative Disorders (1981) (40)
Recurrence after first cerebral infarction in young adults (2000) (40)
Differences in the expression of alkaline phosphatase mRNA in chronic myelogenous leukemia and paroxysmal nocturnal hemoglobinuria polymorphonuclear leukocytes. (1989) (40)
Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations (2017) (40)
Mobilization and collection of PBSC in healthy donors: a retrospective analysis of the Italian Bone Marrow Transplantation Group (GITMO). (1997) (39)
In vivo efficacy of intravenous gammaglobulins in patients with lupus anticoagulant is not mediated by an anti‐idiotypic mechanism (1991) (39)
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases (2019) (38)
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. (2021) (38)
Cerebral vein thrombosis in patients with Philadelphia‐negative myeloproliferative neoplasms An European Leukemia Net study (2014) (38)
Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia (2016) (38)
Intensification of salvage treatment with high‐dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non‐Hodgkin's lymphoma (2001) (37)
Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis. (2020) (37)
Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera (2017) (37)
Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018 (2018) (36)
Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft (1999) (36)
Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients (2017) (36)
Thrombotic thrombocytopenic purpura and high-dose immunoglobulin treatment. (1986) (36)
Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups. (2001) (35)
L-Asparaginase Lowers Protein C Antigen (1984) (35)
All-trans retinoic acid modulates microvascular endothelial cell hemostatic properties. (2003) (34)
Expression of A-myb, but not c-myb and B-myb, is restricted to Burkitt's lymphoma, sIg+ B-acute lymphoblastic leukemia, and a subset of chronic lymphocytic leukemias (1996) (34)
PATIENTS WITH POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA (2013) (34)
bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment. (2005) (34)
Inefficacy of intravenous immunoglobulin in patients with low‐risk thrombotic thrombocytopenic purpura/hemolytic‐uremic syndrome (1992) (33)
European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia (2017) (33)
Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms (2018) (33)
Antiphospholipid antibodies: involvement of protein cofactors. (1993) (33)
A Phase 2A study of the Histone-Deacetylase Inhibitor ITF2357 in Patients with Jak2 V617F Positive Chronic Myeloproliferative Neoplasms (2008) (32)
Prefibrotic myelofibrosis: treatment algorithm 2018 (2018) (32)
Acute undifferentiated leukemia with CD7+ and CD13+ immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features (1992) (32)
Proteolysis of von Willebrand factor is decreased in acute promyelocytic leukaemia by treatment with all‐trans‐retinoic acid (1996) (32)
Increased Levels of β2-Glycoprotein I (aca-Cofactor) in Patients with Lupus Anticoagulant (1992) (32)
Short-term treatment for adult hypergranular and microgranular acute promyelocytic leukemia. (1995) (32)
Abnormal Aggregation and Increased Size of Platelets in Myeloproliferative Disorders (1980) (32)
Rapid retroviral infection of human haemopoietic cells of different lineages: efficient transfer in fresh T cells (1998) (31)
Interaction between platelets and lupus anticoagulant (1988) (31)
Strategies for the treatment of recurrent acute lymphoblastic leukemia in adults. (1996) (30)
Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy (1992) (30)
Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: effects, role of patient pretreatment characteristics, and costs. (1997) (30)
Subunits A and S Inheritance in Four Families with Congenital Factor XIII Deficiency (1978) (30)
Molecular diagnosis and clinical relevance of t(9;22), t(4;11) and t(1 ;19) chromosome abnormalities in a consecutive group of 141 adult patients with acute lymphoblastic leukemia. (1996) (30)
Thrombocytopenia in the antiphospholipid syndrome: pathophysiology, clinical relevance and treatment. (1996) (30)
Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives (2009) (29)
A frameshift mutation leading to type 1 antithrombin deficiency and thrombosis. (1990) (29)
Prolonged Bleeding Time in Patients with Lupus Anticoagulant (1992) (29)
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 (2021) (29)
Risk factors and prevention of vascular complications in polycythemia vera. (1997) (28)
Thalidomide and thrombosis in multiple myeloma (2003) (28)
Maternal Lupus Anticoagulant and Fatal Neonatal Thrombosis (1987) (28)
Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence (2013) (28)
Reductions in JAK2 V617F Allele Burden with Ruxolitinib Treatment in Comfort-II, a Phase 3 Study Comparing the Safety and Efficacy of Ruxolitinib with Best Available Therapy (BAT) (2012) (28)
Results of a randomized study of the JAK inhibitor INC424 compared with best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF). (2011) (28)
Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review (2018) (28)
CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis (2014) (27)
Idiopathic erythrocytosis and other non-clonal polycythemias. (2006) (27)
Low incidence of bleeding from HIV‐related thrombocytopenia in drug addicts and hemophiliacs: Implications for therapeutic strategies (1990) (27)
At the peak of Covid-19 age and disease severity but not comorbidities are predictors of mortality. Covid-19 burden in Bergamo, Italy. (2020) (27)
Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper. (2014) (27)
Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age? (1995) (27)
The use of anthracyclines in adult acute lymphoblastic leukemia. (1995) (27)
Myelokathexis: a rare form of chronic benign granulocytopenia (1984) (27)
Effect of all trans‐retinoic acid (ATRA) on the adhesive and motility properties of acute promyelocytic leukemia cells (1997) (27)
Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. (2004) (27)
Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: Role of the lipoxygenase pathway (1998) (27)
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views (2021) (26)
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis (2020) (26)
Molecular biomarkers of thrombosis in myeloproliferative neoplasms. (2016) (26)
High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen (2009) (26)
The role of idarubicin in adult acute lymphoblastic leukaemia: from drug resistance studies to clinical application. (1997) (26)
BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front‐line therapy for high‐risk patients with diffuse large cell lymphoma (1997) (25)
POEMS syndrome: relapse after successful autologous peripheral blood stem cell transplantation (2007) (25)
Immunoelectrophoretic evidence of a thrombin‐induced abnormality in a new variant of hereditary dysfunctional antithrombin III (AT III ‘Vicenza’) (1983) (25)
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project (2018) (25)
Diagnostic impact of the 2016 revised who criteria for polycythemia vera (2017) (25)
Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF). (2011) (25)
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post‐ASH symposium (2012) (24)
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia (2012) (24)
Interaction between a serum factor and T lymphocytes in gaucher disease (1985) (24)
Establishment and characterization of a new granulocyte-macrophage colony-stimulating factor-dependent and interleukin-3-dependent human acute myeloid leukemia cell line (GF-D8). (1993) (24)
A cathepsin‐like cysteine proteinase proaggregating activity in thrombotic thrombocytopenic purpura (1991) (24)
Ruxolitinib Provides Reductions in Splenomegaly Across Subgroups: An Analysis of Spleen Response in the COMFORT-II Study (2011) (24)
The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis. (2006) (23)
Second cancers in MPN: Survival analysis from an international study (2019) (23)
Prothrombin as cofactor for antiphospholipids (1998) (23)
Evidence-based management of polycythemia vera. (2006) (22)
Are MPNs Vascular Diseases? (2013) (22)
Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera (2018) (22)
Antiphospholipid syndrome associated with immunotherapy for patients with melanoma (1995) (22)
Clinical Trials on Antiphospholipid Syndrome: What is Being Done and What is Needed? (1994) (22)
T cell receptor delta gene organization and expression in normal and leukemic natural killer cells. (1989) (22)
Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis (2019) (22)
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients (2021) (22)
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms (2018) (22)
Need for an accurate molecular diagnosis to assess the donor origin of leukemia relapse after allogeneic stem cell transplantation. (2000) (22)
Subunit A of Factor XIII Regulates Subunit B Plasma Concentration (1981) (21)
Association of large granular lymphocyte/natural killer cell proliferative disease and second hematologic malignancy (1988) (21)
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis (2018) (21)
Clinical outcome after autologous transplantation in non-Hodgkin's lymphoma patients with high international prognostic index (IPI). (1999) (21)
The management of acute myelogenous leukemia in the elderly: Ten‐year experience in 118 patients (1992) (21)
Therapeutic impact of adult-type acute lymphoblastic leukemia regimens in B-cell/L3 acute leukemia and advanced-stage Burkitt's lymphoma. (1996) (21)
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. (2022) (21)
PURE WHITE CELL APLASIA TREATED BY HIGH DOSE INTRAVENOUS IMMUNOGLOBULIN (1984) (21)
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia (2022) (21)
Apparent Heterozygous Type II Protein C Deficiency Caused by the Factor V 506 Arg to GIn Mutation (1995) (21)
Long‐term outcome of adults with acute myelogenous leukaemia: results of a prospective, randomized study of chemotherapy with a minimal follow‐up of 7 years (1991) (20)
Induction‐consolidation with an idarubicin‐containing regimen, unpurged marrow autograft, and post‐graft chemotherapy in adult acute lymphoblastic leukaemia (1999) (20)
Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy. (2013) (20)
The European LeukemiaNet: achievements and perspectives (2011) (20)
Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk. (2007) (20)
Antiphospholipid antibodies and pregnancy. (2003) (20)
Anti-β2-Glycoprotein I and Anti-Prothrombin Antibodies in Antiphospholipid-Negative Patients with Thrombosis (2002) (20)
Long-term results of the HEAVD protocol for adult acute lymphoblastic leukaemia. (1991) (20)
Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper (2019) (20)
A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results (2010) (19)
New and treatment‐relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera (2015) (19)
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study (2021) (19)
European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360–5 - Comment (2012) (19)
Therapeutic efficacy of danazol in myelodysplastic syndromes. (1988) (19)
Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera (2012) (19)
No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials (2017) (19)
Fibrinogen Bergamo I (Aα16Arg → Cys): Susceptibility Towards Thrombin Following Aminoethylation, Methylation or Carboxamidomethylation of Cysteine Residues (1985) (19)
Survival and Risk of Leukemic transformation in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study on 1,104 Patients (2010) (19)
Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data (2018) (18)
The treatment of polycythaemia vera: an update in the JAK2 era (2007) (18)
Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study. (1999) (18)
Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma. (2005) (18)
Long-term Results From a Phase II Open-label Study of Ruxolitinib in Patients With Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea (2014) (18)
RAD001, An Inhibitor of mTOR, Shows Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (PPV/PET MF). (2009) (18)
Antiphospholipid antibodies in patients with previous myocardial infarction (1992) (18)
The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B‐cell and diffuse large B‐cell histologies (2002) (18)
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO‐criteria and stratified by calendar period of diagnosis (2015) (18)
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer. A case-control study. (2019) (17)
Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study (2011) (17)
G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation of resistant or relapsing acute leukemias. (1996) (17)
Effect of all‐trans‐Retinoic acid on the hypercoagulable state of patients with breast cancer (2002) (17)
The Relationship Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) (2013) (17)
Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia. (2000) (17)
A common point mutation producing type 1A antithrombin III deficiency: AT129 CGA to TGA (Arg to Stop). (1991) (17)
Transcriptional and post‐transcriptional regulation of IL‐1β, IL‐6 and TNF‐α genes in chronic lymphocytic leukaemia (1993) (17)
Unexpected remission of acute myeloid leukaemia after GM‐CSF (1994) (17)
Hodgkin'S Disease in Association with Acquired Immunodeficiency Syndrome (Aids): A Report on 36 Patients (1989) (17)
How to manage thrombosis in myeloproliferative neoplasms (2011) (17)
Efficacy and safety of hydroxyurea in patients with essential thrombocythemia. (2001) (17)
Spontaneous Platelet Aggregation in Myeloproliferative Disorders (1973) (17)
Nosocomial outbreak of severe Pseudomonas aeruginosa infections in haematological patients (1993) (17)
Interleukin‐1 and interleukin‐2 control granulocyte‐ and granulocyte‐macrophage colony‐stimulating factor gene expression and cell proliferation in cultured acute myeloblastic leukemia (1990) (17)
Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera (2018) (17)
Antiphospholipid syndrome: definition and treatment. (2003) (17)
Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial (2016) (16)
Prevalence of different anti-phospholipid antibodies in systemic lupus erythematosus and their relationship with the antiphospholipid syndrome. (2001) (16)
Hemostatic system activation in patients with lupus anticoagulant and essential thrombocythemia. (1994) (16)
Molecular Subunits and Transamidase Activity of Factor XIII During Disseminated Intravascular Coagulation in Acute Leukaemia (1980) (16)
The role of anthracyclines in adult acute lymphoblastic leukaemia. (1996) (16)
From palliation to epigenetic therapy in myelofibrosis. (2008) (16)
The Clinical Phenotype of Patients with Essential Thrombocythemia Harboring MPL 515W>L/K Mutation. (2007) (16)
Association of NK-cell lymphoproliferative disease and nephrotic syndrome. (1990) (16)
Expression of A-myb, but not c-myb and B-myb, is restricted to Burkitt's lymphoma, sIg+ B-acute lymphoblastic leukemia, and a subset of chronic lymphocytic leukemias. (1996) (16)
Postoperative Versus Preoperative Initiation of Deep-Vein Thrombosis Prophylaxis with a Low-Molecular-Weight Heparin (Nadroparin) in Elective Hip Replacement (1996) (16)
Large granular lymphocyte/natural killer cell proliferative disease: clinical and laboratory heterogeneity. (2009) (16)
Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia. (2003) (16)
The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts (2017) (15)
Further characterization of platelet‐aggregating cysteine proteinase activity in thrombotic thrombocytopenic purpura (1994) (15)
Modulation of cell proliferation and cytokine production in AML by recombinant interleukin-1 receptor antagonist. (1993) (15)
Leucocyte alkaline phosphatase identifies terminally differentiated normal neutrophils and its lack in chronic myelogenous leukaemia is not dependent on p210 tyrosine kinase activity (1999) (15)
Diluted Russell's viper venom time and colloidal silica clotting time for the identification of the phospholipid-dependent inhibitors of coagulation. (1997) (15)
ACE inhibitors and cytoreductive therapy in polycythemia vera. (2017) (15)
Molecular characterization of a new recombination of the SIL/TAL‐1 locus in a child with T‐cell acute lymphoblastic leukaemia (2002) (15)
Inhibition of cancer procoagulant by peptidyl diazomethyl ketones and peptidyl sulfonium salts. (1989) (15)
Blood oxidative status and selectins plasma levels in healthy donors receiving granulocyte-colony stimulating factor (2006) (15)
Electroimmunoassay of Plasma Subunits-A and -S in a Case of Congenital Fibrin Stabilizing Factor Deficiency (1974) (15)
Three-year ef ﬁ cacy, safety, and survival ﬁ ndings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelo ﬁ brosis (2013) (14)
Increased production of mononuclear cell procoagulant activity in Hodgkin's disease. (1983) (14)
Integrated use of morphology, cytochemistry, and immune marker analysis to identify acute leukaemia subtypes. (1989) (14)
Hereditary Dysfunctional Antithrombin III (AT-III Vicenza) (1981) (14)
Immunophenotypic evaluation of circulating T-cell clones in hypereosinophilic syndromes with or without abnormal CD3 and CD4 lymphocytes. (2004) (14)
Aspirin in low-risk essential thrombocythemia, not so simple after all? (2011) (14)
Flow cytometry of leucocyte alkaline phosphatase in normal and pathologic leucocytes (1997) (14)
Stat 1 Is Induced and Activated by All-Trans Retinoic Acid in Acute Promyelocytic Leukemia Cells (1997) (14)
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. (2017) (14)
Establishment of human acute myelogenous leukemia lines secreting interleukin‐1β in SCID mice (1995) (14)
The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis (2014) (14)
Spectrum of platelet aggregation abnormalities in myeloproliferative diseases (1981) (14)
The new WHO classification for essential thrombocythemia calls for revision of available evidences (2020) (14)
Innovative haematological parameters for early diagnosis of sepsis in adult patients admitted in intensive care unit (2017) (14)
Special Issues in Myeloproliferative Neoplasms (2011) (13)
Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results (2015) (13)
Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia. (2002) (13)
Lymphokine Production in Ty Lymphoproliferative Disorders (1986) (13)
Reinforced HEAV'D therapy for adult acute lymphoblastic leukemia: Improved results and revised prognostic criteria (1993) (13)
A Phase II Study of the HDAC Inhibitor Givinostat In Combination with Hydroxyurea In Patients with Polycythemia Vera Resistant to Hydroxyurea Monotherapy (2011) (13)
Induction of cytotoxicity by interleukin‐2 in tγ‐lymphoproliferative disorders (1986) (13)
All-Trans-Retinoic Acid andBleeding/Thrombosis (2003) (13)
INTRAVENOUS GAMMAGLOBULIN, ANTIPHOSPHOLIPID ANTIBODIES, AND THROMBOCYTOPENIA (1988) (13)
THERAPY WITH HUMAN RECOMBINANT ERYTHROPOIETIN IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (1992) (13)
Feasibility of a randomized clinical trial for the prevention of recurrent thrombosis in the antiphospholipid syndrome: the WAPS project. Provisional Steering Committee of the Warfarin in Antiphospholipid Syndrome (WAPS) Study. (1996) (13)
Evaluating survival after allogeneic bone marrow transplant for chronic myeloid leukaemia in chronic phase: a comparison of transplant versus no‐transplant in a cohort of 258 patients first seen in Italy between 1984 and 1986 (1993) (13)
A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia. (1998) (13)
Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification (2014) (13)
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project (2018) (13)
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients (2019) (13)
Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response (2013) (13)
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis (2020) (12)
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. (2018) (12)
Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). (1999) (12)
High-dose treatment with autologous bone marrow support as consolidation of first remission in younger patients with acute myelogenous leukaemia. (2000) (12)
Indications for lowering platelet numbers in essential thrombocythemia. (2003) (12)
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera (2022) (12)
Histone H1 degrees is synthesized by human lymphocytic leukemia cells but not by normal lymphocytes (1987) (12)
Platelet 5-hydroxytryptamine transport and storage in myeloproliferative disorders. (2009) (12)
Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients? (2012) (11)
Two dimensional immunoelectrophoresis of antithrombin III during disseminated intravascular coagulation in acute leukemia. (1978) (11)
INCREASED RESPONSE TO ARACHIDONIC ACID AND U-46619 AND RESISTANCE TO INHIBITORY PR0STAGLANDING IN PATIENTS WITH CHRONIC MYELOPROLIFE RATIVE DISORDERS (1987) (11)
DURATION OF FIRST REMISSION IN LEUKAEMIC RECIPIENTS OF LEUCOCYTE‐POOR BLOOD COMPONENTS (1990) (11)
Monoclonal lymphocytosis with villous lymphocytes: a chronic lymphoproliferative disease of CD11c+ B-cells. (1991) (11)
Human T-cell lymphoblastic lymphoma expressing the T-cell receptor gamma/delta established in immune-deficient (bg/nu/xid) mice. (1993) (11)
Identification of two novel isoforms of the ZNF162 gene: a growing family of signal transduction and activator of RNA proteins. (1997) (11)
Constitutive expression of IL‐1β, M‐CSF and c‐fms during the myeloid blastic phase of chronic myelogenous leukaemia (1992) (11)
Surface immunoglobulin intensivity and p67 (CD5) antigen expression define different forms of B-cell chronic lymphocytic leukaemia. (1987) (11)
Institutional performance and dose intensity as prognostic factors in adult ALL. (1995) (11)
Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients. (2001) (10)
Impaired production of mononuclear cell procoagulant activity in chronic lymphocytic leukaemia. (1983) (10)
Health-related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II study. (2012) (10)
Long-term follow-up of recovered MPN patients with COVID-19 (2021) (10)
Long‐term haematological reconstitution following BEAM and autologous transplantation of circulating progenitor cells in non‐Hodgkin's lymphoma (1997) (10)
Antiblastic therapy and thrombosis (1992) (10)
A short low‐dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes (2009) (10)
Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups. (2002) (10)
Bleeding and thrombosis in acute lymphoblastic leukemia. (1993) (10)
A hitherto undescribed defect of platelet coagulant activity in polycythaemia vera and essential thrombocythaemia. (1979) (9)
Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. (2021) (9)
Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells. (1999) (9)
Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. (2018) (9)
Reduced Generation of Procoagulant Activity by Endotoxin‐stimulated Mononuclear Cells from Patients with Chronic Myeloid Leukaemia (1981) (9)
MULTIPLE MYELOME IN A PAIR OF TWINS (1987) (9)
Feasibility of randomised clinical trials in rare diseases: the case of polycythemia vera. (1996) (9)
Treatment of acute lymphoblastic leukemia in adults (1985) (9)
Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms (2019) (8)
Management of venous thromboembolism in myeloproliferative neoplasms (2017) (8)
Investigation of chronic lymphocytosis in adults. (1988) (8)
Effect of Aspirin on Platelet 5-Hydroxytryptamine and Beta-Thromboglobulin Plasma Levels in Patients with Myeloproliferative Diseases (1982) (8)
Distinct Hemostatic Profile of Leukocytes in Essential Thrombocythemia (ET) Carrying the JAK2 V617F Mutation. (2005) (8)
Factor VIII immunological assay. An evaluation of several methods using whole plasma (1974) (8)
Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia (2021) (8)
The Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs), (2011) (8)
Fibrin cross-linking in congenital factor XIII deficiency. (1980) (8)
Short‐term remission induction and consolidation therapy for adult acute myelogenous leukemia (2006) (8)
Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases (2021) (8)
Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment (2022) (8)
Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms (2014) (8)
Association of cytokine levels and reductions in spleen size in COMFORT-II, a phase III study comparing ruxolitinib to best available therapy (BAT). (2012) (8)
Purification of antithrombin ‘Vicenza’: a molecule with normal heparin affinity and impaired reactivity to thrombin (1985) (8)
Coagulation Studies in a Case of Severe Congenital Hypofibrinogenemia (1972) (8)
Insomnia, Quality Of Life and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG) (2013) (8)
Facing erythrocytosis: Results of an international physician survey (2019) (8)
Defective platelet aggregation induced by platelet activating factor in myeloproliferative disorders: deficiency of an aspirin-independent mechanism? (1986) (7)
Two serum IgG-M components of different light-chain types in a case of Hodgkin's disease. (1976) (7)
Management of essential thrombocythemia. (1999) (7)
Chemoimmunotherapy with R-CHOP or High Dose Sequential Therapy with Autologous Stem Cell Transplantation (R-HDS) for High Risk Diffuse Large B-Cell Lymphomas Patients: Results of the Randomized R-HDS0305 Trial by Gruppo Italiano Terapie Innovative Nei Linfomi (GITIL) (2012) (7)
The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms (2022) (7)
Relationship between Hb and HbA2 concentrations in beta-thalassemia trait and effect of iron deficiency anaemia. (1976) (7)
Reduced Platelet Factor X-Activating Activity (1981) (7)
Clinical trials in myeloproliferative disorders: looking forward. (2005) (7)
Acute and Subacute Outcome Predictors in Moderate and Severe Traumatic Brain Injury: A Retrospective Monocentric Study. (2019) (7)
Extreme thrombocytosis in low‐risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies (2021) (7)
Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms (2016) (7)
Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia. (1998) (7)
Platelet function after busulphan in chronic myeloproliferative disorders. (1983) (7)
Anti-beta2-glycoprotein I and anti-prothrombin antibodies in antiphospholipid-negative patients with thrombosis: a case control study. (2002) (7)
Conventional therapeutic options have limited impact on MPN symptoms: Insights from a prospective analysis of the MPN-SAF TSS (2012) (7)
Expertise-Based Management in Essential Thrombocythemia and Polycythemia Vera (2007) (7)
Recurrent thrombosis in patients with polycythemia vera or essential thrombocythemia : efficacy of treatment in preventing rethrombosis in different clinical settings (2006) (7)
Direct Oral Anticoagulants for Myeloproliferative Neoplasms (MPN-DOACs): Results from an International Study on 442 Patients (2020) (7)
Clinical and biological effects of erythropoietin treatment of myelodysplastic syndrome. (1993) (6)
The chronic proliferative disease of large granular lymphocytes. (1989) (6)
Prognostic factors in chronic myeloid leukemia. Relationship with interferon and bone marrow transplantation. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. (1993) (6)
Clinical Significance of JAK2 V617F Homozygosity in the Chronic Myeloproliferative Disorders. A Study on 1306 Patients. (2006) (6)
Infusion of Donor Derived Cytokine Induced Killer Cells May Induce Clinical Remission with Limited GVHD in Patients Relapsing after Allogeneic Stem Cell Transplantation. (2006) (6)
Transcriptional and post-transcriptional regulation of IL-1 beta, IL-6 and TNF-alpha genes in chronic lymphocytic leukaemia. (1993) (6)
RBC-transfusion guidelines update. (2012) (6)
Health-Related Quality of Life and Symptoms in Myelofibrosis Patients Treated with Ruxolitinib Versus Best Available Therapy (2011) (6)
Platelet-derived mitogenic activity and bone marrow fibrosis in myeloproliferative disorders. (1990) (6)
REDUCED PLATELET MITOGENIC ACTIVITY IN MYELOPROLIFERATIVE DISORDERS (1986) (6)
Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: A study of the MYSEC group (2019) (6)
Generation of procoagulant activity by hairy cells in response to endotoxin and phorbol esters. (1986) (6)
Comparison of low molecular weight heparin CY 216 and unfractionated heparin in preventing post-operative venous thromboembolism in general surgery: a preliminary results of a cooperative study (1990) (6)
Novel insights into the biology and treatment of chronic myeloproliferative neoplasms* (2015) (6)
Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG) (2013) (6)
Intensive retreatment of adults and children with acute lymphoblastic leukemia (1992) (6)
Treatment target in polycythemia vera. (2013) (6)
Cancer survivorship programs: time for concerted action (2014) (6)
Hemorrhage and thrombosis in acute leukemia (2009) (6)
Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients (2005) (6)
Lack of cross-reactivity between anticardiolipin antibodies and glycosaminoglycans. (1990) (6)
The management of ‘low‐risk’ and ‘intermediate‐risk’ patients with primary thrombocythaemia (1999) (6)
Von Willebrand's disease in Italy. A study of 13 families from a small area in the province of Vicenza. (1974) (6)
Factors for rapid and sustained hematopoietic reconstitution by circulating progenitor-cell transplantation in non-Hodgkin’s lymphoma (1996) (6)
Histone H1(0) is synthesized by human lymphocytic leukemia cells but not by normal lymphocytes. (1987) (6)
IgM gammopathy and the lupus anticoagulant syndrome in habitual aborters. (1986) (6)
Antiphospholipid antibodies and melanoma: a link? (1992) (6)
Addressing Key Clinical Care and Clinical Research Needs in Severe Pediatric Traumatic Brain Injury: Perspectives From a Focused International Conference (2021) (6)
Does the βTG/PF4 Ratio Have Any Value in Myeloproliferative Diseases? (1984) (6)
Concurrent multiple myeloma and chronic lymphocytic leukemia. (1984) (6)
Apoptosis by anthracyclines at therapeutic concentrations in MDR1+ human leukemic cells. (1999) (6)
Second versus first wave of COVID-19 in patients with MPN (2022) (6)
Fibrinogen Bergamo III and fibrinogen Torino: two further variants with hereditary molecular defects in fibrinopeptide A. (1987) (6)
A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM) (2014) (6)
What is the standard treatment in essential thrombocythemia (2002) (5)
Bleeding on patients with autoimmune thrombocytopenic purpura and normal platelet count. (2009) (5)
Comparison of Price-Jones curves obtained with an electronic corpuscle counter in normal subjects and in patients with thalassaemia and iron deficiency. (1973) (5)
Idiopathic thrombocytopenic purpura and pregnancy. Maternal platelet count and antiplatelet antibodies do not predict the risk of neonatal thrombocytopenia (1985) (5)
Diagnostic Criteria for Hematopoietic Stem Cell Transplantation-Associated Microangiopathy (TAM): Results of a Consensus Process by an International Working Group. (2005) (5)
RAEB IN PATIENT WITH CHRONIC GRANULATED T‐LYMPHOCYTOSIS (1987) (5)
Platelet Malonyldialdehyde and Spontaneous Aggregation During Ischaemic Attacks of Patients with Polycythaemia Vera (1979) (5)
Leukocytosis as an Independent Risk Factor for Thrombosis in Polycythemia Vera. (2006) (5)
Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia. (1993) (5)
Treatment of the lymphoid blast crisis of chronic myeloid leukemia. (1987) (5)
Idarubicin Activity Against Multidrug-Resistant (mdr-1+) Cells is Increased by Cyclosporin A (1998) (5)
From leeches to interferon: should cytoreduction be prescribed for all patients with polycythemia vera? (2020) (5)
The Aspirin Tolerance Test in von Willebrand’s Disease (1977) (5)
Three-month mortality in permanently bedridden medical non-oncologic patients. The BECLAP study (permanently BEdridden, creatinine CLearance, albumin, previous hospital admissions study). (2019) (5)
Selective Targeting of the JAK2V617F Mutation in Polycythemia Vera and Essential Thrombocythemia by ITF2357, a Novel Histone Deacetylase Inhibitor. (2007) (5)
Dissociation between factor VIII (activity and antigen) and ristocetin-induced platelet aggregation in von Willebrand's disease. (1975) (5)
A retrospective study on oral anticoagulant prophylaxis in 103 Italian patients with hereditary thrombophilia and thrombosis (1990) (5)
The effects of phenphormin on blood fibrinolysis in diabetes mellitus. (1969) (5)
Low Prevalence of JAK2 Val617Phe Mutation in Patients with Idiopathic Erythrocytosis. (2005) (5)
Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results. (1998) (5)
Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group (2016) (5)
Inhibition of ticlopidine of platelet adhesion to human venous subendothelium in patients with diabetes. (1988) (5)
Hematopoietic Progenitor Cells From Patients with Chronic Mountain Sickness Lack the JAK2V617F Mutation, Show Hypersensitivity to Erythropoietin and Are Inhibited by Statins. (2009) (5)
Role of anthracyclines in the treatment of adult acute lymphoblastic leukemia. (1996) (5)
Acute Lymphoblastic Leukaemia Cells Carrying the t(12;21) Translocation Are Highly Sensitive to Alemtuzumab Mediated Cell Lysis. (2005) (4)
Antiphospholipid Antibodies and Associated Clinical Manifestations. (1996) (4)
Benefit of Rituximab Addition to High-Dose Programs with Autograft for B-Cell Lymphoma: A Multicenter GITIL Survey on 957 Patients. (2006) (4)
Doxorubicin and m-AMSA induced DNA damage in blast cells from AML patients. (1991) (4)
How Epidemiology of Polycythemia Vera Has Changed in the Last 10 Years: Results From the Whole Prospective Cohort of Patients in Cyto-PV Trial As Compared with Eclap Prospective Cohort (2012) (4)
Clinical sensitivity to anthracyclines in PH/BCR+ acute lymphoblastic leukemia. (1999) (4)
Refining prognostication of thrombosis in ET (2016) (4)
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): An International Prospective Validation Trial In 402 Patients (2010) (4)
Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm (2015) (4)
LUPUS ANTICOAGULANT AND REPEATED ABORTIONS: A CASE- CONTROL STUDY (1987) (4)
Infection and hemorrhage in elderly acute myeloblastic leukemia and primary myelodysplasia. (1993) (4)
Confirmation and improvement of Sokal's prognostic classification of Ph+ chronic myeloid leukemia: The value of early evaluation of the course of the disease (2005) (4)
Defective Fibrin Crosslinking in Acute Leukemia (1984) (4)
Myeloablative therapy with autologous bone marrow transplantation (ABMT) as consolidation of first remission in younger patients with acute myelogenous leukaemia (AML). (1993) (4)
Factor-XIII subunits-A and -S in congenital deficiency and in acute myeloblastic leukemia. (1974) (4)
Symptomatic burden in myelofibrosis (MF): Prospective international assessment in 128 MF patients. (2011) (4)
Red blood cell survival and hyperbilirubinaemia in the Gilbert's syndrome. (1976) (4)
Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms (2017) (4)
Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia – very long follow‐up (2014) (4)
Systematic Evaluation of DNA-Based Quantitative-Polymerase Chain Reaction (Q-PCR) Assays to Track Treatment Response in Patients with JAK2-V617F Associated Myeloproliferative Neoplasms: A Joint European LeukemiaNet/ MPN&MPNr-EuroNet Study (2011) (4)
Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings (2019) (4)
Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin (2019) (4)
Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin (2019) (4)
Reductions in JAK2V617F allele burden with ruxolitinib treatment in COMFORT-II, a phase III study comparing the safety and efficacy of ruxolitinib to best available therapy (BAT). (2012) (4)
AM 580 , a Stable Benzoic Derivative of Retinoic Acid , Has Powerful and Selective Cyto-Differentiating Effects on Acute Promyelocytic Leukemia Cells (2002) (4)
Multiple myeloma in a pair of twins. (1987) (4)
Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms (2020) (3)
JAK2V617F mutation persists in blasts and mature cells of transformedJAK2V617F‐positive‐myeloproliferative neoplasia: A European leukemia net (ENL) study (2010) (3)
A Phase 2 Study Of Ruxolitinib In Patients With Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasm. Preliminary Results (2013) (3)
No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from ECLAP and CYTO-PV clinical trials (2017) (3)
Frontline High Dose Sequential Chemotherapy with Rituximab (R-HDS) and Autologous Stem Cell Transplantation Induces High Rates of Complete Response and Prolongs Survival in Mantle Cell Lymphoma (MCL). (2006) (3)
Recombinant Versus High-sensitivity Conventional Thromboplastin: A Randomized Clinical Study in Patients on Oral Anticoagulation (1994) (3)
Symptom Severity and Clinical Variables of Polycythemia Vera Patients with Splenomegaly, Phlebotomy Requirements and/or Hydroxyurea Use : a Retrospective Evaluation of 1334 Patients (2014) (3)
First Italian family with abnormal antithrombin III (an-III vicenza). (1981) (3)
Thrombosis and Malignancy (2001) (3)
Gender Differences and MPN Symptom Burden : An Analysis by the MPN Quality of Life International Study Group (MPN-QOL ISG) (2014) (3)
Prednisone Corrects the Prolonged Bleeding Time in Thrombocythaemia (1982) (3)
One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity (2022) (3)
Intensive chemotherapy for acute lymphoblastic leukaemia in adults. (1990) (3)
Chronic myeloid disorders, excluding CML (2004) (3)
Cerebral Vein Thrombosis In Patients With Myeloproliferative Neoplasms (2013) (3)
The Management of Polycythaemia Vera. (1997) (3)
Hodgkin's Disease in 50 Intravenous Drug Users with HIV-Infection. (1991) (3)
Reduced platelet factor X-activating activity: a possible contribution to bleeding complications in polycythaemia vera and essential thrombocythaemia. (1981) (3)
Long-Term Follow-Up of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Peripheral T-Cell Lymphomas at Diagnosis. (2004) (3)
[Clinical significance and predictive value of laboratory tests in thrombosis associated with antiphospolipid antibodies]. (1997) (3)
Bone Marrow BCL2/IgH+ Cells at Diagnosis and Not FCGRIIIA Polymorphism Predict Response in Follicular Non-Hodgkin’s Lymphoma Patients Treated with Sequential CHOP and Rituximab. (2005) (3)
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative (2019) (3)
MIPSS70: Mutation-Enhanced Prognostic System for Transplant Age Patients with Primary Myelofibrosis (2017) (3)
INTERACTION BETWEEN LUPUS ANTICOAGULANT AND PLATELETS (1987) (3)
Rituximab: a new therapeutic tool for primary immune thrombocytopenic purpura? (2003) (3)
The natural history of monoclonal villous lymphocytosis: a chronic lymphoproliferative disorder of CD11c+ B cells. (1996) (3)
Towards a Better Understanding of Epidemiology, Survival and Treatment in Myeloproliferative Neoplasms: Results of the European Leukemianet Registry (ERNEST study) (2014) (3)
Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic (2021) (3)
Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells (2008) (3)
In vitro platelet adhesion to vascular subendothelium: Studies in patients with polycythaemia vera (1988) (3)
Optimizing investigator-led oncology research in Europe (2012) (3)
Prolonged Remission in Adult B-ALL (L3) and Advanced Burkitt’s Lymphoma Using Acute Leukaemia Regimens: Study of 34 Patients (1998) (3)
Essential thrombocytemia and ischemic stroke: Report of six cases (1994) (3)
Spontaneous platelet aggregation in myeloproliferative disorders. A preliminary study. (1973) (3)
MACOP-B for advanced stage large cell lymphoma (DLCL). More is better? Italian Multiregional Cooperative Study Group (IMCSGL). (1991) (3)
Brief report Characteristics and clinical correlates of MPL 515WL/K mutation in essential thrombocythemia (2016) (2)
PS1458 RISK FACTORS AND OUTCOME OF ACUTE MYELOID LEUKEMIA SECONDARY TO POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT (2019) (2)
A Phase I Study of the Proteasome Inhibitor Bortezomib in Patients with Myelofibrosis. (2007) (2)
Immunological and genotypic analysis of human Tγ-lymphoproliferative disorders (1986) (2)
Retrospective analysis of treatment of acute myeloblastic leukemia in patients more than 55 years old. (1982) (2)
Illustrated State‐of‐the‐Art Capsules of the ISTH 2020 Congress (2021) (2)
Stage-modi ¢ ed international prognostic index e ¡ ectively predicts clinical outcome of localized primary gastric di ¡ use large B-cell lymphoma (1999) (2)
A Large-Scale Trial Testing the Intensity of Cytoreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera (CYTO-PV trial) (2012) (2)
Heparin does not modify plasma daunomycin disappearance in acute leukaemia patients. (1980) (2)
Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19. (2021) (2)
PRIMARY MYELOFIBROSIS, POST-ET AND POST-PV MYELOFIBROSIS HAVE DISTINCT CLINICAL PROFILES AND SYMPTOMATIC BURDENS : AN ANALYSIS BY THE MPN QUALITY OF LIFE INTERNATIONAL STUDY GROUP (MPN-QOL ISG) (2015) (2)
Changes in the lactate and pyruvate levels of the blood and of the lactate-pyruvate ratio in patients with diabetes treated with phenethylbiguanide. (1969) (2)
Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs) (2015) (2)
Thrombotic and Hemorrhagic Complications after Surgery in Patients with Essential Thrombocythemia and Polycythemia Vera. (2006) (2)
Role of anthracycline dose intensity in adult Philadelphia chromosome/BCR-ABL positive and negative B-lineage acute lymphoblastic leukemia (1999) (2)
Preliminary Results of a Risk-Oriented Program for B-Lineage Adult Acute Lymphoblastic Leukemia (ALL): The Collaborative Italian Study 08/96 (2001) (2)
Fibrinogen survival with 75-seleniomethionine in acute myeloblastic leukemia during polychemotherapy. (1976) (2)
Second Versus First Wave of COVID-19 in Patients with MPN (2021) (2)
Normal vascular prostacyclin generation in patients with chronic myeloproliferative disorders. (1985) (2)
A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group (2014) (2)
The Management of Essential Thrombocythaemia. (1997) (2)
Autologous PBSC transplant for late onset AML after mafosfamide-purged and TBI-containing autologous BMT. (1995) (2)
An agenda for future research projects in polycythemia vera and essential thrombocythemia (2020) (2)
Superb Microvascular Imaging (SMI) Compared with Color Doppler Ultrasound for the Assessment of Hepatic Artery in Pediatric Liver Transplants: A Feasibility Study (2022) (2)
A PROGNOSTIC MODEL to PREDICT SURVIVAL In WHO-DEFINED ESSENTIAL THROMBOCYTHEMIA: A STUDY by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) (2011) (2)
Hereditary dysfunctional protein C (protein C "Bergamo II") diagnosed by a rapid assay. (1987) (2)
Leukocytosis and thrombosis in polycythemia vera: can clinical trials settle the debate? (2019) (2)
Associations between gender , disease features and symptom burden in the MPN population : An analysis by the MPN QOL International Working Group (2016) (2)
Establishment and characterization of a new granulocyte-macrophage colony-stimulating factor-dependent and interleukin-3-dependent human acute myeloid leukemia cell line (GF-D8) (1993) (2)
Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms (2018) (2)
Desferrioxamine B: Reversible side effects of high daily doses (1975) (2)
A Globally Applicable "Triple AAA" Risk Model for Essential Thrombocythemia Based on Age, Absolute Neutrophil Count, and Absolute Lymphocyte Count (2021) (2)
Comments on pre‐fibrotic myelofibrosis and how should it be managed (2019) (2)
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients (2022) (2)
Diagnostic and prognostic significance of platelet-bound IgG measurement in immune thrombocytopenic purpura (1982) (2)
Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs (2015) (1)
JAK2V617F Mutation Persists IN Blasts and Mature CELLS of Transformed- JAK2V617F-POSITIVE-MYELOPROLIFERATIVE Neoplasia: A European LEUKEMIA NET (ENL) STUDY (2010) (1)
Short and Long-Term Risk of Major Cardiovascular Events after Ischemic Stroke or Transient Ischemic Attack in Myeloproliferative Neoplasms (2017) (1)
Anticoagulant activity of anticoardiolipin antibodies is mediated by β2-glycoprotein I (1992) (1)
Prefibrotic myelofibrosis: treatment algorithm 2018 (2018) (1)
Limited Success with a Postremission Strategy Comprising Conventional Consolidation and High-Dose Treatment (HDT) with Autologous Peripheral Progenitor Cell (PBPC) Support for Adult Acute Lymphoblastic Leukaemia (ALL) (2003) (1)
C ombined MV-trans Retinoic Acid and Idarubicin (AIDA) Therapy (1997) (1)
A new family with congenital factor XII deficiency. (1975) (1)
Incidence of Secondary Myelodysplastic Syndrome/Acute Leukemia in 1,266 Lymphoma Patients Following High-Dose Therapy and Autograft: A Study from GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). (2006) (1)
Myeloproliferative Neoplasms, Critical Concepts And Management (2012) (1)
Minimal Residual Disease (MRD) and Risk-Oriented Therapy in Adult Acute Lymphoblastic Leukemia (ALL). (2005) (1)
Frequency, characteristics, and outcome of patients with COVID-19 pneumonia and "silent hypoxemia" at admission: a severity-matched analysis. (2022) (1)
Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms (2018) (1)
Long-term survival in adult acute leukemia. A multicenter study of 56 patients. (1982) (1)
PO-26 Activated factor VII–Antithrombin complex (FVIIa-AT) in patients with acute promyelocytic leukemia (APL) (2007) (1)
Shc Overexpression Induces Selective Hypersensitivity to GM-CSF and Prevents Apoptosis of the GM-CSF-Dependent Acute Myelogenous Leukemia Cell Line GF-D8 (1998) (1)
Platelets in Thrombotic and Non-thrombotic Disorders: Thrombocytosis and thrombocythemia (2002) (1)
Microparticle-Associated Thrombin Generation and Procoagulant Activity Is Increased In Patients with Essential Thrombocythemia (2010) (1)
Telomere Length In Ph - Negative Chronic Myeloproliferative Neoplasms: It Is Reduced According to JAK2 V617F Mutation Allele Burden and It Is Not Affected by Cytoreductive Treatment with Hydroxyurea (2010) (1)
Deciphering the Individual Contribution of Absolute Neutrophil, Lymphocyte and Monocyte Counts to Thrombosis Risk in Patients with Myeloproliferative Neoplasms (2021) (1)
Risk Factors for Thrombosis Among 1,545 Patients with Polycythemia Vera: An International Study. (2012) (1)
Impact Of Splenomegaly On Mpn Symptoms And Association With Clinical Features : An Analysis By The Mpn Quality Of Life International Study Group (2016) (1)
Palpitations And Arrhythmia In 3649 High-Risk Patients With Essential Thrombocythemia : Results From The Prospective Long-Term Observational Exels Study (2016) (1)
The course of monoclonal ‘villous’ lymphocytosis over 15 years of follow-up: progression to SLVL or spontaneous clinical but not molecular remission (2003) (1)
Pegylated interferon alpha-2a in patients with myeloproliferative neoplasms (MPN): international experience in 115 cases (2012) (1)
Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group (2016) (1)
Neutrophil-to-Lymphocyte Ratio (NLR) Is a Risk Factor for Venous Thrombosis in Polycythemia Vera (2021) (1)
History of the myeloproliferative neoplasms (2020) (1)
A recombination event in the closely linked plasminogen and apolipoprotein(a) gene loci (1995) (1)
Symptom Burden in "Low Risk PV" Frequently Is Problematic and May Justify Earlier Intervention with Cytoreductive Therapy: An MPN-QOL Study Group Study (2020) (1)
Different Types of von Wiilebrand’s Disease (vWd): A Study of 101 Cases (1975) (1)
The Value of βTG/PF4 Ratio in Patients with High Platelet Count – Reply (1985) (1)
Myeloproliferative disorders: a time of new definitions Outflow from New Horizons in Haematology Meeting, 9–10 March 2007 (2007) (1)
[Urinary iron after desferrioxamine. I. Effectiveness and tolerance of high doses of the drug]. (1972) (1)
Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls (2019) (1)
IN ADULT ACUTE MYELOID LEUKAEMIA (AML) ALL RISK SUBSETS BENEFIT FROM A SEQUENTIAL HIGH-DOSE PROGRAMME AS EARLY RESCUE OF FIRST INDUCTION FAILURE: A REPORT FROM NORTHERN ITALY LEUKAEMIA GROUP (NILG) (2010) (1)
Risk-Adapted Therapy of Adult Acute Myeloid Leukemia (AML): Safety and Efficacy of Repetitive HD-ARA-C Courses with Low-Dose Autologous Blood Stem Cell Support. (2005) (1)
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID‐19 (2022) (1)
SIUM ON ONCOLOGY PRACTICE : HEMATOLOGICAL MALIGNANCIES (2005) (1)
Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasms. A Study Of The IWG-MRT In 475 Subjects (2013) (1)
Failure to measure plasma activated factor XIII during disseminated intravascular coagulation (1981) (1)
First-Line Therapy and Special Issues Management in Polycythemia Vera and Essential Thrombocythemia (2012) (1)
Proteomic profiling of cerebrospinal fluid to detect potential biomarkers for multiple sclerosis (2008) (1)
P010 Incidence and risk factors of secondary myelodysplastic syndrome/acute leukemia occurrence following peripheral blood progenitor cell autograft: a GITIL (Gruppo Italiano Terapie Innovative Nei Linfomi) survey on 1266 lymphoma patients (2007) (1)
Interactions between antiphospholipid antibodies and blood cells (1995) (1)
ADP-Induced Whole Blood Aggregometry and Platelet-Associated Thrombin Generation (TG) In Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Patients (2010) (1)
Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial (2022) (1)
Association between lupus anticoagulant and epilepsy (1987) (1)
TREATMENT OF DIC ASSOCIATED WITH APL. RESPONSE (1990) (1)
Migratory capacity of large granular lymphocytes from T-gamma-lymphoproliferative disorders. (1986) (1)
Platelet dysfunction in splenectomized patients with hairy cell leukemia. (1986) (1)
Management of Thrombocytopenia in Hughes Syndrome (2006) (1)
Lymphokine production in T gamma lymphoproliferative disorders. (1986) (1)
Factor VIII Related Properties in Platelets of Patients with von Willebrand’s Disease (VWD) (1977) (1)
Response to “Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions” by Heidel et al. (2018) (1)
[Value and limits of corticosteroids therapy during the acute phase of myocardial infarct]. (1969) (1)
Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients (2014) (1)
Carboplatin-Based High-Dose Therapy for Refractory Acute Myeloid Leukaemia (1998) (1)
[The effect of O2 inhalation on respiratory function in obese patients]. (1969) (1)
The Stage-Modified IPI (MIPI), Histology and a Combined Treatment Influence the Clinical Outcome of 401 Patients with Primary Extranodal Head and Neck B-Cell Lymphomas (PHNBCL) (IELSG 23). (2005) (1)
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT. (2022) (1)
The Addition of Rituximab to High Dose Sequential Chemotherapy (HDS) Programs with Autologous Transplantation Significantly Improves the Outcome of Patients with Refractory or Relapsed B-Cell Non Hogkin’s Lymphoma. (2005) (1)
Long-term results of high-dose chemotherapy (HDCT) supported by hematopoietic circulating (ASCT) or bone marrow (BMT) stem cell autografting as first salvage treatment for refractory or relapsed Hodgkin's lymphoma. (2006) (1)
Hodgkin's disease in association with acquired immunodeficiency syndrome (AIDS). A report on 36 patients. Gruppo Italiano Cooperativo AIDS and Tumori. (1989) (1)
Pre-Autologous Stem Cell Transplantation (ASCT) Treatment with Rituximab Does Not Impair Stem Cell Harvest and Engraftment in Untreated Patients with Diffuse Large B-Cell Lymphoma (B-DLCL) at Poor Prognosis. (2005) (1)
Procoagulant Cell Activities in Acute Leukemia (1992) (1)
Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasms: A Study of the AGIMM & IWG-MRT Groups in 519 Subjects (2014) (1)
Leukapheresis in hairy cell leukemia. (1983) (0)
Impact of Mutation Status of ASXL1, EZH2, SRSF2, IDH1/2 on Clinical Phenotype and Prognosis in Patients with Post-Polycythemia and Post-Essential Thrombocythemia Myelofibrosis: An AGIMM Study (2014) (0)
expert panel primary myelofibrosis: recommendations from an ad hoc international diagnostic criteria for polycythemia vera, essential thrombocythemia, and Proposals and rationale for revision of the World Health Organization (2013) (0)
Consideration of Symptom Burden Based Treatment in PV and ET Patients: An Analysis By MPN International Quality of Life Study Group (2016) (0)
its expression by leukemic cells myeloblastic leukemia by interleukin-1 receptor antagonist and lack of Modulation of cell proliferation and cytokine production in acute (2011) (0)
NATURAL HISTORY OF POLYCYTHEMIA VERA. AUTHORS' REPLY (1996) (0)
Increased Response to Arachidonic Acid and U-46619 and Resistance to Inhibitory Prostaglandins in Patients with Chronic Myeloproliferative Disorders (1988) (0)
High-Sensitivity C-Reactive Protein (hs-CRP) and Pentraxin 3 (PTX3) Are Increased in Essential Thrombocythemia and Polycythemia Vera. (2009) (0)
Prolonged Survival of Lymphoma Patients Achieving Complete Remission Following High-Dose Sequential Chemotherapy and Autograft (HDS Program): A GITIL (Gruppo Italiano Terapie Innovative Nei Linfomi) Retrospective Study on 1,266 Patients. (2006) (0)
High Response Rate with Favorable Survival Projections in High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving R-CHOP-14 or Early Intensified Chemotherapy with Rituximab and Autograft (R-HDS): Results of the Interim Analysis of A GITIL Prospective Multicenter Phase III Study. (2009) (0)
Pegylated Interferon Alpha – 2a in Patients with Myeloproliferative Neoplasms (MPN): International Experience in 115 Cases (2011) (0)
thrombosis in the antiphospholipid syndrome 2-glycoprotein I, antiprothrombin antibodies, and the risk of β - Anti (2013) (0)
Antiphospholipid antibodies and intravascular thrombosis. (1994) (0)
Platelet vWF, ADAMTS-13, and Neutrophil Activation in Patients with Essential Thrombocythemia (ET) (2007) (0)
Unmet Needs for Symptom Control in Essential Thrombocythemia with Front Line Therapy (2015) (0)
[Fibrinolytic activity of the urine in chronic glomerulonephritis]. (1969) (0)
Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients (2018) (0)
Impact of V617F JAK2 Mutation on Monocyte Tissue Factor and Procoagulant Activity in Patients with Essential Thrombocythemia(ET) or Polycythemia VERA (PV) (2008) (0)
Editor's/Publisher's Disclaimer (1998) (0)
Prospective Clinical and Epidemiological Evaluation of rHuEPO in the Routine Care of a Network of Hematological Centers. (2004) (0)
Efficacy of High-Dose Sequential Chemotherapy and Autograft for Transformed Non Hodgkin’s B Cell Lymphoma: Results of a Retrospective Analysis from GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). (2007) (0)
Contents, Vol. 54, 1975 (1975) (0)
[Thrombosis and anti-tumor chemotherapy]. (1991) (0)
41 Management of Thrombocytopenia in (2000) (0)
Peripheral blood progenitor cells for allogenic transplantation of resistant and relapsing acute leukemias Molecular evidence of full hematologic engraftment (1996) (0)
essential thrombocythemia and polycythemia vera Thrombin generation and activated protein C resistance in patients with (2013) (0)
Essential thrombocythemia treatment algorithm 2018 (2018) (0)
Gigantic cutaneous lymphoma following Di Bella's therapy. (2002) (0)
[Various therapeutic prerogatives of phenethylbiguanide in diabete mellitus. Effect of the drug on body weight, blood cholesterol, fibrinolysis, and blood lactic acid]. (1969) (0)
Arterial Versus Venous Events in Essential Thrombocythemia and Their Impact on Overall and Thrombosis Free Survival (2015) (0)
A randomized clinical trial on the prevention of platelet refractoriness by the use of filtered blood components (1990) (0)
[Siderinuria caused by deferoxamine. II. The siderinuric increment obtained by association with ascorbic acid]. (1973) (0)
Early Application of Anthracyclines in Adult Acute Lymphoblastic Leukemia (ALL) (2001) (0)
Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN) (2022) (0)
Index autorum ad Vol. 54 (2004) (0)
Relationship between Ristocetin-induced platelet aggregation and factor VIII (activity and antigen) in v. Willebrand's disease (1974) (0)
Minimal Residual Disease (MRD)-Oriented Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Results of Northern Italy Leukemia Group Study 09/00. (2007) (0)
[Behavior of lactate, pyruvate and the blood lactate-pyruvate ratio in diabetics during treatment with phenethylbiguanide]. (1969) (0)
[Blood fibrinolysis and ischemic disease of the myocardium in diabetes mellitus]. (1969) (0)
Finding the needle by modelling the haystack: Pulmonary embolism in an emergency patient with cardiorespiratory manifestations (2021) (0)
[Type II congenital dyserythropoietic anemia (HEMPAS) with high familial incidence]. (1975) (0)
[Effect of the administration of phenyl-ethyl-biguanide on tolerance to oral administration of glucose in chronic uremia]. (1969) (0)
Management of Patients with Essential Thrombocythemia (2009) (0)
[Studies of the water-electrolyte composition of the body in chronic glomerulonephritis measured with the aid of Na22 and Br82 and of 4-amino-antipyrine]. (1968) (0)
P995: MYELOID NEOPLASMS-ASSOCIATED GENE VARIANTS IN 639 PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT (2022) (0)
Platelet functions in von Willebrand's disease. (1974) (0)
Anticardiolipin antibodies binding to activated platelets and platelet microparticles is dependent on β2-glycoprotein I (1992) (0)
Comments on ELN Recommendations to Diagnosis, Prognosis and Treatment of Polycythemia Vera and Essential Thrombocythemia (2012) (0)
[Hypoinosis and the excess of urinary urokinase in a case of "essential hematuria"]. (1968) (0)
ACQUIRED RESISTANCE TO ACTIVATED PROTEIN C (APC) IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA (ET) (2007) (0)
[Management of quantitative and qualitative platelet defects]. (1999) (0)
Abnormal reactivity with thrombin of a new variant of dysfunctional antithrombin (AT ‘Vicenza’) (1984) (0)
[Prospective assessment of the agreement of instruments for measuring the hospital nursing workload: the Swiss Method, the Karnofsky Performance Status Scale and the subjective perception of the nurses]. (2017) (0)
PO-25 Predictive value for VTE of hemostatic markers in patients with multiple myeloma receiving thalidomide (2007) (0)
The Role of Anthracycline S in the Management of Adult Acute Lymphoblastic Leukaemia (1996) (0)
Immune (Idiopathic) Thrombocytopenic Purpura (ITP): Treatment Pattern and Splenectomy Rate from a Multinational Prospective Observational Study (2008) (0)
History of BCR-ABL-negative chronic myeloproliferative disorders (2008) (0)
Split-Course High-Dose ARA-C Plus Idarubicin and Multidrug Blockade by short Cyclosporin-A Infusion for Refractory Acute Myeloid Leukemia (2001) (0)
Changes of JAK2 V617F Allele Burden Over Time in Patients with Polycythemia Vera or Essential Thrombocythemia: A Retrospective Study of 172 Patients. (2009) (0)
Leucocytosis is a risk factor for recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia (2009) (0)
Pharmacokinetic study of the new cyclosporine-a formulation (neoral™) in adult ALLO-BMT recipients (2000) (0)
[Congenital deficiency of fibrin stabilizing factor (factor XIII)]. (1968) (0)
Potent Inhibition of EEC Colony Formation in JAK2V617F PV and ET by Low Doses of ITF2357, a New Histone Deacetylase Inhibitor. (2006) (0)
Non-myeloablative conditioning before allogeneic stem cell transplantation in adult acute lymphoblastic leukemia (2003) (0)
Patterns of presentation of thrombosis in contemporary patients with PV and ET (2016) (0)
essential thrombocythemia, polycythemia vera, and myelofibrosis Long-term survival and blast transformation in molecularly annotated (2014) (0)
PB2212 FACING ERYTHROCYTOSIS: RESULTS OF AN INTERNATIONAL PHYSICIANS’ SURVEY (2019) (0)
1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events (2022) (0)
The synthetic retinoic acid receptor (RAR)-gamma agonist CD437 reduces procoagulant activity and induces apoptosis in breast cancer cells (2003) (0)
[Erythrocyte spectra in the diagnosis of microcytoses and macrocytoses]. (1975) (0)
[Clinical staging of chronic lymphatic leukemia: review of the literature and new proposal]. (1982) (0)
Anagrelide of its Use in the Management of Essential Thrombocythaemia (2006) (0)
[Daily serum complement (C'H50, beta 1C globulin) and erythrocyturia in active chronic glomerulonephritis during immunosuppressive therapy with azathioprine]. (1969) (0)
Evolving management of essential thrombocythaemia (2007) (0)
Similar Rate of Thrombosis in Essential Thrombocythemia and Polycythemia Vera Patients after Stratification for JAK2 V617F Allele Burden. (2008) (0)
(IPSET-thrombosis) essential thrombocythemia - thrombosis in World Health Organization Development and validation of an International Prognostic Score of (2013) (0)
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score (2022) (0)
Response: Thrombocytosis in low-risk ET patients (2008) (0)
Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms (2018) (0)
The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following Intensive Therapy and Autograft Correlates with the Type of Cells Grafted: A Survey on 1,347 Lymphoma Patients Receiving the High-Dose Sequential (HDS) Program. (2007) (0)
New Isoforms of the ZFM1 Gene: a Growing Family of Signal Transduction and Activator of RNA (STAR) Proteins (1998) (0)
[Current clinical relevance of disseminated intravascular coagulation]. (1989) (0)
leukemia Constitutive expression of the interleukin-6 gene in chronic lymphocytic (2011) (0)
Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO) (2022) (0)
Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients (2012) (0)
Optimal Timing of Autologous Bone Marrow Transplantation for Patients with Hodgkin’s Lymphoma1 (1989) (0)
Polycythaemia vera (2020) (0)
A frameshift mutation in the antithrombin gene leading to type 1 deficiency and thrombosis (1990) (0)
[Studies of blood platelet adhesiveness and plasmatic thromboplastinogenesis in diabetes mellitus]. (1968) (0)
Favorable Influence of Rituximab with High Dose Sequential Chemotherapy (R-HDS) Programs and Autologous Stem Cell Transplantation (ASCT) in Salvage Treatment for Patients with Refractory or Relapsed B-Cell Non-Hodgkin’s Lymphoma. (2006) (0)
[Studies on intermediate metabolism in chronic uremia. Effect of intravenous administration of glucagon on blood lactate pyruvate and alpha-ketoglutarate in the suprahepatic and peripheral veins]. (1969) (0)
Successful treatment with heparin of cerebral vein thrombosis in young patients (1992) (0)
Comprar Myeloproliferative Neoplasms, Critical Concepts And Management | Tiziano Barbui | 9783642249884 | Springer (2012) (0)
Receiving Granulocyte Colony-Stimulating Factor Neutrophil Activation and Hemostatic Changes in Healthy Donors (1999) (0)
Possible Prognostic Benefit from ABMT in First Remission Adult Acute Lymphoblastic Leukemia (2000) (0)
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis (2020) (0)
Acknowledgement Letter CDI 32 (12) (2012) (0)
Establishment and Characterization of a New Granulocyte-Macrophage Colony-Stimulating Factor-Dependent and Interleukin-3-Dependent Human Acute Myeloid Leukemia Cell Line ( GF-DS ) (2003) (0)
The international consensus classification of myeloid neoplasms and acute leukemias: Myeloproliferative neoplasms (2023) (0)
Symptom Burden and Quality of Life in High-Risk Essential Thrombocythemia and Polycythemia Vera Patients Receiving Hydroxyurea or Pegylated Interferon Alfa-2a: Results of Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 Trials (2020) (0)
based on the burden of JAK2V617F mutated allele Identification of patients with poorer survival in primary myelofibrosis (2013) (0)
[Contribution to the knowledge of the disease due to PTA deficiency]. (1965) (0)
[Thrombelastographic study of marrow blood in liver cirrhosis, with particular reference to its fibrinolytic activity]. (1967) (0)
Symptomatic profiles of 1334 polycythemia vera patients: implications of inadequately controlled disease (2016) (0)
Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018 (2018) (0)
Update of the Italian Registry on Antiphospholipid antibodies (1992) (0)
The new WHO classification for essential thrombocythemia calls for revision of available evidences (2020) (0)
Salvage Therapy for Resistant or Relapsing Acute Lymphoblastic Leukemia (ALL) after Idarubicin-Based Induction (2003) (0)
[Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease]. (1978) (0)
Cellular blood components in haemostasis and thrombosis : implications from myeloproliferative disorders : proceedings of the conference held in Bergamo on May 7-8, 1987 (1988) (0)
Risk Factors for Thrombosis in WHO-Defined Early/Prefibrotic Myelofibrosis: An International Study of 264 Patients, (2011) (0)
[Significance of some humoral and cytological indices in active stages of Hodgkin's disease]. (1972) (0)
polymorphonuclear leukocytes myelogenous leukemia and paroxysmal nocturnal hemoglobinuria Differences in the expression of alkaline phosphatase mRNA in chronic (2013) (0)
Author and Subject Index (2001) (0)
Prospective Validation of the Italian Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Italian) In 186 MPN Patients (2010) (0)
Response to: Ruxolitinib withdrawal due to the COVID-19 (2021) (0)
Use of histone deacetylase inhibitors for the treatment of negative myeloproliferative syndromes Philadelphia (2009) (0)
Real time PCR for molecular monitoring of minimal residual disease in multiple myeloma patients undergoing autologous transplantation with in vitro purged hematopoietic stem cells (2000) (0)
Recurrent Venous Thrombosis in Patients with Polycythemia Vera and Essential Thrombocythemia (2007) (0)
High-Dose Cytosine Arabinoside in the Treatment of Acute Lymphoblastic Leukaemia (1994) (0)
Il farmacista e i network diagnostico-terapeutici in ematologia (2016) (0)
DISSEMINATED INTRAVASCULAR COAGULATION (DIC) AND ACUTE LEUKEMIA:IDENTIFICATION OF A NEW CELLULAR PROCOAGULANT (1987) (0)
[On some irregular aspects of the thromboelastogram in chronic uremia]. (1968) (0)
previously untreated patients with follicular lymphoma Monitoring of minimal residual disease after CHOP and rituximab in (2013) (0)
Prevalence of antithrombin III deficiency in blood donors selected for personal or familial history of venous thrombosis (1985) (0)
Validation of the International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPSET) in Patients with Pre-Fibrotic Primary Myelofibrosis (2019) (0)
Sensitivity and Specificity of Laboratory Parameters to Detect Early/Prefibrotic Myelofibrosis in 857 Patients with Essential Thrombocythemia. A Diagnostic Algorithm (2011) (0)
Congenital dyserythropoietic anemia, type II (Hempas) first five reported cases in Italy (1974) (0)
LeukemiaNet: A transnational model for cooperative leukemia research. (2011) (0)
Clonal hematopoiesis and inflammation: a link with thrombosis and malignancy (2022) (0)
HOMOZYGOSITY FOR JAK2V617F IDENTIFIES MPD PATIENTS WITH A MORE SYMPTOMATIC DISEASE A RETROSPECTIVE STUDY ON 989 PATIENTS FROM THE GIMEMA-MPD WORKING PARTY (2006) (0)
Current Treatment Approaches of Polycythemia Vera (2006) (0)
Breakthrough infections in MPN-COVID vaccinated patients (2022) (0)
Association between Hb O Padova [alpha 30 (B 11) Glu leads to Lys] and Rendu-Osler disease. (1983) (0)
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Neutrophil Activation and Hemostatic Changes in Healthy Donors Receiving Granulocyte Colony-Stimulating Factor (2016) (0)
Rebuttal to the Letter to the Editor by Dr. A. Girolami (1993) (0)
Development of an MF patient reported outcome (PRO) tool for FDA qualification: Comprehensive literature search and physician cognitive debriefing results (2016) (0)
10 Myeloproliferative neoplasms Ph- negative (2010) (0)
[Question of thrombocytopathy in von Willebrand's disease]. (1974) (0)
Clotting system activation in patients with cancer undergoing major surgery: The role of heparin prophylaxis (1992) (0)
[Radioisotope study of Hodgkin's desease with special reference to the morphological and functional aspects of the spleen]. (1972) (0)
The 1.5 Million Platelet Count Threshold in Essential Thrombocythemia: Phenotype and Genotype Correlates and Relevance to Vascular Events (2021) (0)
Gene Rearrangements and Expression in Normal and Leukemic Large Granular Lymphocytes / Natural Killer Cells (2005) (0)
Hydroxyurea: the comparator in studies with new anti-JAK2 inhibitors (2009) (0)
Cysteine proteinase activity in Thrombotic thrombocytopenic Purpura (TTP) (1992) (0)
Therapy of Polycythemia Vera and Essential Thrombocythemia (2011) (0)
WAPS (warfarin in the antiphospholipid syndrome) study Clinical significance of different antiphospholipid antibodies in the (2013) (0)
Red blood cell deformability in polycythaemia vera does not depend on hypochromic microcytosis (2016) (0)
Expression of the T Cell Receptor δ Gene in Normal and Leukemic Natural Killer Cells1 (1990) (0)
Clinical Relevance of JAK2 V617F Allele Burden in Primary and Post-Polycythemic/Post-Thrombocythemic Myelofibrosis (2008) (0)
Comparison of the Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Across Nine Linguistic Translations Among an International Sample of 1,851 Myeloproliferative Neoplasm (MPN) Patients. (2012) (0)
[Treatment of 17 cases of non-lymphoblastic acute leukemia with a combination of daunorubicin, cytosine and arabinoside]. (1975) (0)
P1009: PREDICTORS OF HOSPITALIZATION AND SEVERE OUTCOMES IN PATIENTS WITH MPN AND COVID-19 (2022) (0)
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project (2018) (0)
Prognostic Factors in Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia (2001) (0)
Impaired production ofmononuclear cell procoagulant activity inchronic lymphocytic leukaemia (1983) (0)
An International Multicenter Project on Secondary Myelofibrosis (2016) (0)
thrombocythemia: a retrospective survey Post-surgery outcomes in patients with polycythemia vera and essential (2013) (0)
Three Abnormal Fibrinogen Variants with the Same Amino Acid Substitution ly 275 Arg + His ) : (2018) (0)
Pregnancies in Patients with Philadelphia Negative Chronic Myeloproliferative Disorders: Interim Report of the European LeukemiaNet Data Base (2008) (0)
[Methodological studies for the determination of protein 8 and of its biological activity]. (1974) (0)
PO-28 Increased thrombin generation (TG) potential of platelets from myeloproliferative neoplasms (2010) (0)
Intrinsic and method-induced variation of the bleeding time and related parameters (2007) (0)
POINT MUTATIONS PRODUCING TYPE-1A ANTITHROMBIN-III DEFICIENCY (1991) (0)
PS1468 IMPACT OF CYTOREDUCTIVE DRUGS ON SECOND CANCER IN MYELOPROLIFERATIVE NEOPLASMS (2019) (0)
Updated Results of an Age-Adapted Consolidation Strategy with ABMT ( 50 Years) in Adult Acute Myeloid Leukemia (2000) (0)
Polycythemia vera treatment algorithm 2018 (2018) (0)
(NB4) activity induced by a human promyelocytic leukemia-derived cell line All-trans-retinoic acid counteracts endothelial cell procoagulant (2011) (0)
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases (2018) (0)
Preface (2001) (0)
essential thrombocythemia Characteristics and clinical correlates of MPL 515W>L/K mutation in (2013) (0)
JAK2 Val617Phe Mutation Correlates with the Risk of Thrombosis in Patients with Essential Thrombocythemia. (2005) (0)
Organization of a Randomized Clinical Trial for the Prevention of Recurrent Thrombosis in the Antiphospholipid Syndrome: the WAPS Project (Warfarin in Antiphospholipid Syndrome) (1998) (0)
Acute leukemia in polycythemia vera (2009) (0)
Induction of cytotoxicity by interleukin-2 in T gamma-lymphoproliferative disorders. (1986) (0)
Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol. (1989) (0)
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group (2014) (0)
Changes in fibrinolysis and clotting parameters in acute promyelocytic leukemia (APL) patients treated with al-transretinoic acid (ATRA) (1994) (0)
Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera (2018) (0)
High-dose chemotherapy/ABMT in 72 patients with advanced resistant Hodgkin's disease (HD). An Italian study group (1988) (0)
Altered Platelet Factor X Activating Activity in Myeloproliferative Disorders (1979) (0)
OP47 Polycythaemia vera: new approaches, new targets (2007) (0)
Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies (2022) (0)
myelofibrosis phase 3 study comparing ruxolitinib with best available therapy for Three-year efficacy, safety, and survival findings from COMFORT-II, a (2013) (0)
Autoimmunity and second malignancy in large granular lymphocytic leukaemia. (1989) (0)
Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study (2019) (0)
enrolled in a prospective observational study Acute leukemia in polycythemia vera: an analysis of 1638 patients (2013) (0)
Increased prevalence of autoimmune thyroid disease after COVID-19: A single-center, prospective study (2023) (0)
Impact Of Ruxolitinib On The Natural History Of Patients With Primary Myelofibrosis: A Retrospective Comparison Of The DIPSS and The Comfort-2 Cohorts (2013) (0)
Subject Index Vol. 95, 1996 (1996) (0)
The GIMEMA (Gruppo Italiano Malattie Ematologiche dell’Adulto) experience on type I Gaucher disease. (2002) (0)
Appropriate management of Polycythemia Vera with cytoreductive drug therapy (2022) (0)
Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data (2018) (0)
Flow Cytometry of Leukocyte Alkaline Phosphatase in Human Hematopoietic Cells (1998) (0)
[Diagnostic value of kinetocardiography in coronary cardiopathy]. (1969) (0)
Time- and Dose-Response Relationships of Imatinib Mesylate (Glivec) Therapy for Chronic Hypereosinophilic Syndromes. (2005) (0)
[Bromsulphalein clearance and hyperbilirubinemia in Gilbert's syndrome]. (1975) (0)
Driver mutations ( JAK2 V617F , MPL W515L/K or CALR ), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera (2017) (0)
PF671 RATE OF THROMBOSIS IN CONTEMPORARY PATIENTS WITH POLYCYTHEMIA VERA UNDER HYDROXYUREA REMAINS EXCEEDINGLY HIGH. RESULTS OF SYSTEMATIC REVIEW AND METANALYSIS (2019) (0)
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion (2018) (0)
[Congenital deficiency of antithrombin III]. (1990) (0)
[Behavior of blood lactate after oral glucose load in normal subjects. Effect of phenethylbiguanide administration]. (1969) (0)
Natural History of Polycythemia Vera (1996) (0)
Contents, Vol. 95, 1996 (1996) (0)
Management of Patients with Polycythemia Vera (2009) (0)
[The question of thrombocytopathy in Von Willebrand's disease]. (1975) (0)
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms (2018) (0)
Leukemia ... the next questions. (1993) (0)
Erratum: Platelet‐induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera (2011) (0)
Prognosis of Veno-Occlusive Disease after Stem Cell Transplantation in the DF-VOD Trial. On behalf of the DF-VOD Investigators:. (2004) (0)
P olycythemia vera (2008) (0)
PO-75 Thrombin generation in patients with essential thrombocythemia (ET) (2007) (0)
[Essential thrombocythemia: antiaggregants]. (1991) (0)
Clinical Phenotype and Genotype Correlations with Time to Progression into Post Polycythemia Vera and Post Essential Thrombocythemia Myelofibrosis (2017) (0)
[Experience with clinical therapy of diabetes mellitus with oral administration of combined chlorpropamide and phenylbiguanide]. (1970) (0)
A Predictive Model for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of 1,252 Cases Performed by the Intergruppo Italiano Linfomi (IIL). (2004) (0)
CANCER-ASSOCIATED THROMBOTIC DISEASE Myeloproliferative neoplasms and thrombosis (2017) (0)
Prognostic relevance of CD20 in adult B-cell precursor acute lymphoblastic leukemia (2010) (0)
Calreticulin Mutation Does Not Modify the International Prognostic Score for Predicting the Risk of Thrombosis Among 1,150 Patients with Essential Thrombocythemia (2014) (0)
Site‐specific venous thrombosis in essential thrombocythemia: Impact on subsequent vascular events and survival (2022) (0)
and Allogeneic Transplantation Mobilized Circulating Progenitor Cells: Adequacy for Autologous - Factor Innovative Two-Step Negative Selection of Granulocyte Colony-Stimulating (2013) (0)
Acquired thrombophilia: antiphospholipid syndrome and essential thrombocythemia (2002) (0)
Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects (2022) (0)
international expert panel and primary myelofibrosis: recommendations from an ad hoc diagnostic criteria for polycythemia vera, essential thrombocythemia, Proposals and rationale for revision of the World Health Organization (2009) (0)
Index rerum ad Vol. 54 (1975) (0)
Antithrombin III and Other Natural Inhibitors of Coagulation (1985) (0)
An Reduced Plasma Membrane Ca 2+ -atpase Function in Platelets from Patients with Non-insulin-dependent Diabetes Mellitus Letters to the Editor (0)
[Semiautomatic study of platelet aggregation]. (1972) (0)
Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms (2018) (0)
Myeloproliferative Neoplasms. (2017) (0)
Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET (2023) (0)
Subunit S and A Ratio in Congenital and Acquired Deficiency of Factor XIII (1979) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Tiziano Barbui?

Tiziano Barbui is affiliated with the following schools: